Boston, MA 05/13/2014 (wallstreetpr) – Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and commercializes products used in the manufacturing of biological drugs. The company announced the hiring of Tony J. Hunt, a former executive at Life Technologies Corp (NASDAQ:LIFE).
The company announced that Mr. Hunt will fill the Chief Operating Offering position that it recently created within its ranks. Mr. Hunt recently served as President of BioProduction at Life Technologies. His roles involved the development and growth of the bioprocessing business where he earned a reputation for his efforts in the building of analytics franchises and downstream purification. At Repligen Corporation (NASDAQ:RGEN) Mr. Hunt will be concerned with the manufacturing and oversees commercial operations.
According to Repligen CEO Walter C. Herlihy, having Mr. Hunt in the company will support speedy expansion of commercial operations. His expertise in the life science industry will also support diversification at Repligen Corporation (NASDAQ:RGEN) now that the company is pursuing multiple opportunities in the bioprocess business.
Life Technologies was acquired by Thermo Fisher Scientific Inc. (NYSE:TMO) in February this year.
Career highlight
With many opportunities showing in the life sciences sector, Repligen Corporation (NASDAQ:RGEN) is trying to attract talents that can support its efforts in expanding market share while capturing new opportunities in the industry. Mr. Hunt’s lengthy career in the life science space offers that perfect fit. Mr. Hunt joined Life Technologies as General Manager and rose through the ranks to the position of president in charge of a division with about 200 employees.
Achieve growth
Growth is at the top of the agenda at Repligen Corporation (NASDAQ:RGEN). The company seeks to attract more customers and introduce new products to realize revenue growth. The company is also taking more austerity measures to support savings that can be reinvested or returned to investors in the form of dividend or stock repurchase.
The company reported positive 1Q2014 whereby EPS was 13 cents, beating consensus estimate of 7 cents. Revenue was $16.33 million, ahead of $15.14 million projected by analysts.
